Thousands of men could live longer with prostate cancer after taking a new drug combination. Around 10,000 men a year in the UK are estimated to have an aggressive form of prostate cancer, which is normally treated with hormone therapy and radiotherapy. A study found also giving them a drug called abiraterone halves their risk of dying from the cancer over six years. Abiraterone was denied to men with more advanced prostate cancer in January, after the National Institute for Health and Care Excellence, which approves drugs, ruled it was not cost-effective and should not be offered routinely. The expensive daily tablets cost £35,500 a year privately, although how much the NHS pays is not known. However the new British-led trial in a different group of men, whose prostate cancer had not spread, found abiraterone, taken for just two years, greatly improved their chances of survival. Experts hope the drug could be made available on the NHS ‘soon’ following the results. …